icone plus
Contact Abonnez-vous aux actualités
Reason for request
Inclusion
Clinical Benefit
Substantial
Substantial actual benefit
Clinical Added Value
important
KALYDECO offers a substantial improvement in actual benefit (IAB II) in the treatment of cystic fibrosis in patients aged 6 years and older with the G551D-CFTR mutation.
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
fLNG0hA2434djYeK
Listen
